What is HC Wainwright’s Estimate for ESPR FY2028 Earnings?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – HC Wainwright decreased their FY2028 EPS estimates for shares of Esperion Therapeutics in a report issued on Thursday, January 23rd. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings of $0.16 per share for the year, down from their prior estimate of $6.05. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.28) per share.

Other research analysts also recently issued research reports about the stock. Cantor Fitzgerald initiated coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 target price on the stock. StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. JMP Securities reiterated a “market outperform” rating and issued a $7.00 price target on shares of Esperion Therapeutics in a research report on Thursday. The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a research report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Esperion Therapeutics currently has an average rating of “Hold” and a consensus target price of $7.25.

Esperion Therapeutics Stock Performance

Shares of NASDAQ ESPR opened at $2.10 on Monday. The firm’s 50 day moving average price is $2.46 and its 200-day moving average price is $2.17. The company has a market cap of $413.78 million, a PE ratio of -3.28 and a beta of 1.03. Esperion Therapeutics has a 52-week low of $1.58 and a 52-week high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The company had revenue of $51.63 million for the quarter, compared to the consensus estimate of $55.44 million. During the same period in the prior year, the business posted ($0.37) earnings per share.

Hedge Funds Weigh In On Esperion Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Wasatch Advisors LP lifted its position in Esperion Therapeutics by 38.4% during the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock valued at $38,521,000 after purchasing an additional 6,483,070 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Esperion Therapeutics by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after buying an additional 171,609 shares in the last quarter. Marshall Wace LLP lifted its holdings in Esperion Therapeutics by 94.2% during the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock valued at $9,554,000 after buying an additional 2,087,635 shares in the last quarter. State Street Corp lifted its holdings in Esperion Therapeutics by 2.7% during the 3rd quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock valued at $6,360,000 after buying an additional 99,802 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Esperion Therapeutics by 1.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,069,117 shares of the biopharmaceutical company’s stock valued at $3,414,000 after buying an additional 19,588 shares in the last quarter. 47.39% of the stock is owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.